---
title: "covid-19_and_majestec-1"
date: "2024-08-24"
tags:
  - building
---

> [!NOTE]
> ðŸŒ± created from: [[majestec-1]]

# covid-19_and_majestec-1

- Design: Phase 1/2 clinical trial, multi-center, open-label
- Number of patients: 165
- Patients characteristics: Patients with relapsed/refractory multiple myeloma
- Agent: Teclistamab 1.5 mg/kg weekly
- Treatment line: Patients received teclistamab as treatment
- Trial Acronym/NCTId Number: NCT03145181/NCT04557098
- Compare efficacy:

| Parameter            | Result |
| -------------------- | ------ |
| Infections           | 80.0%  |
| Grade 3/4 infections | 55.2%  |
| COVID-19             | 21.2%  |
| Neutropenia          | 65.5%  |

- Highlight of toxicity: Grade 3/4 infections occurred in 55.2% of patients, including COVID-19 and respiratory infections.
- One-line summary: Teclistamab treatment in patients with relapsed/refractory multiple myeloma led to a high rate of infections, including COVID-19, highlighting the importance of monitoring and management of infections during treatment.

> Nooka AK, Rodriguez C, Mateos MV, et al. Incidence, timing, and management of infections in patients receiving teclistamab for the treatment of relapsed/refractory multiple myeloma in the MajesTEC-1 study. Cancer. 2024;130(6):886-900. doi:10.1002/cncr.35107
